Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Array Biopharma Inc (NASDAQ:ARRY)

5.81
Delayed Data
As of Jul 31
 +0.06 / +1.04%
Today’s Change
2.98
Today|||52-Week Range
8.59
+22.83%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$828.5M

Company Description

Array BioPharma Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Its proprietary drug development pipeline focuses on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. It also collaborates with pharmaceutical and biotechnology companies under which the firm has out-licensed certain proprietary drug programs for further research, development, and commercialization. The company was founded by Kevin Koch, Anthony Piscopio, K.C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

Contact Information

Array BioPharma, Inc.
3200 Walnut Street
Boulder Colorado 80301
P:(303) 381-6600
Investor Relations:
(303) 386-1193

Employees

Shareholders

Other institutional63.42%
Mutual fund holders37.96%
Individual stakeholders14.18%

Top Executives

Ron SquarerChief Executive Officer & Director
Andrew R. RobbinsChief Operating Officer
David J. HorinChief Financial Officer
Nick A. SaccomanoChief Scientific Officer
Robert E. WinklerVice President-Clinical Research & Development